Covenant High Plains Surgery Center

First and only free-standing ambulatory surgery center in West Texas to perform robot-assisted total knee replacement surgery using the state-of-the-art Stryker MAKO® surgical robot

West Texas patients seeking outpatient knee replacement surgery have a new, high-quality, cost-effective choice for their care at a nationally accredited center that meets the highest standards for patient safety and quality.

Dr. David Shephard announced today the successful completion of West Texas first outpatient robot-assisted knee replacement surgery at a free-standing ambulatory surgery center (ASC) using the Stryker MAKO® surgical robot.

Dr. Shephard is a Johns Hopkins fellowship-trained and board-certified orthopedic surgeon, and a partner at Lubbock Sports Medicine. He has performed more than a thousand robot-assisted knee replacements at Covenant Medical Center and Grace Surgical Hospital and welcomed the opportunity to extend this treatment option to a completely new environment.

“For appropriate candidates, an ASC is a safe, convenient, and cost-effective option, and we are proud to be the first center in West Texas to offer patients this choice,” stated Dr. Shephard. “Patients who undergo robot-assisted total knee replacement at our center will often go home the same day, at most the next morning. Studies show that recovery at home can be beneficial to the patient, speeding the healing process, and reducing the risk of infection.”

The Ambulatory Surgery Center Association notes that “ASCs have transformed the outpatient experience for millions of Americans by providing them with a more convenient alternative to hospital-based outpatient procedures—and done so with a strong track record of quality care and positive patient outcomes,” and ASCs save Medicare and patients billions of dollars each year by offering excellent care at lower overall costs.

“The Stryker MAKO® robotic platform was selected because of its strong track record of proven results,” stated CHPSC Administrator Alfonso del Granado. “And now, for the first time, patients in West Texas have the option to benefit from this innovative technology in an ambulatory surgery center. Too often, patients have not been able to afford the treatment options available at large hospitals. With this new program, we are demonstrating our commitment to offer patients the best care in West Texas.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy